{"nctId":"NCT03292809","briefTitle":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","startDateStruct":{"date":"2017-10-19","type":"ACTUAL"},"conditions":["Dry Eye Disease"],"count":328,"armGroups":[{"label":"CyclASol Ophthalmic Solution","type":"EXPERIMENTAL","interventionNames":["Drug: CyclASol topical ocular, eye drops"]},{"label":"Vehicle Ophthalmic Solution","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle topical ocular, eye drops"]}],"interventions":[{"name":"CyclASol topical ocular, eye drops","otherNames":["Ciclosporine (CsA)"]},{"name":"Vehicle topical ocular, eye drops","otherNames":["Vehicle"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed ICF (Informed Consent Form) and HIPAA (Health Insurance Portability and Accountability Act)\n* Patient-reported history of DED in both eyes\n* Current use of OTC (over-the-counter) and/or artificial tears for dry eye symptoms\n* Ability and willingness to follow instructions, including participation in all study assessments and visits\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing or planning a pregnancy\n* Unwillingness to submit a urine pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control\n* Clinically significant slit-lamp findings or abnormal lid anatomy at screening\n* Ocular/periocular malignancy\n* History of herpetic keratitis\n* Active ocular allergies or ocular allergies that may become active during the study period\n* Ongoing ocular or systemic infection at screening or baseline\n* Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study\n* History of no response to previous topical Cyclosporine A and/or use of topical Cyclosporine A or Liftigrast within 2 months prior to screening\n* Intraocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period\n* Presence of uncontrolled systemic diseases\n* Presence of known allergy and/or sensitivity to the study drug or its components","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Total Corneal Fluorescein Staining at Day 29","description":"CFS was assessed in each eye using the National Eye Institute (NEI) scale.\n\nA standardized grading system of 0-3 is used for each of the five areas on each cornea. Grade 0 will be specified when no staining is present. The maximum total score for each eye is 15. Higher values describe greater staining and corneal damage.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"2.59"},{"groupId":"OG001","value":"-2.2","spread":"2.73"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Ocular Surface Disease Index at Day 29","description":"The OSDI score is a composite measure built on 12 questions,with totals ranging from 0 to 100, and higher scores representing a worse disease index.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.08","spread":"18.650"},{"groupId":"OG001","value":"-5.37","spread":"15.291"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":162},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Visual acuity reduced","Instillation site pain","Vision blurred"]}}}